Genomics and dementia — new drug targets ahead?

  • H. A. M. Mucke
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 62)


Pharmacogenetics — the application of genomic technologies such as gene sequencing and gene expression analysis to drugs — is beginning to make its impact on central nervous system drug development. The mapping of genes (including their polymorphisms) and their expression in normal and disease states to discover new drug targets will also change the scenery of dementia therapeutics’ development completely because it uses a “bottom-up” strategy, identifying genes whose expression is changed in dementia or by drug therapy. Drugs identified this way should be mechanistically novel, more potent and specific, and probably quicker to develop. Pharmaco-genomics can however also greatly contribute to the improvement of drugs targeting currently known receptors and enzymes.


Alzheimer Disease Vascular Dementia Estrogen Receptor Alpha Gene Glutamate Transporter GLAST Estrogen Receptor Gene Polymorphism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alvarez-Arcaya A, Combarros O, Llorca J, Sanchez-Guerra M, Berciano J, Fernandez-Luna JL (2001) The ¡ª 491 TT apolipoprotein E promoter polymorphism is associated with reduced risk for sporadic Alzheimer’s disease. Neurosci Lett 304: 204–208Google Scholar
  2. Beckstrom H, Julsrud L, Haugeto O, Dewar D, Graham DI, Lehre KP, Storm-Mathisen J, Danbolt NC (1999) Interindividual differences in the levels of the glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer’s disease. J Neurosci Res 55: 218–229PubMedCrossRefGoogle Scholar
  3. Bertram L, Guenette S, Jones J, Keeney D, Mullin K, Crystal A, Basu S, Yhu S, Deng A, Rebeck GW, Hyman BT, Go R, Mclnnis M, Blacker D, Tanzi R (2001) No evidence for genetic association or linkage of the cathepsin D (CTSD) exon 2 polymorphism and Alzheimer disease. Ann Neurol 49: 114–116PubMedCrossRefGoogle Scholar
  4. Brandi ML, Becherini L, Gennari L, Racchi M, Bianchetti A, Nacmias B, Sorbi S, Mecocci P, Senin U, Govoni S (1999) Association of the estrogen receptor alpha geneGoogle Scholar
  5. polymorphisms with sporadic Alzheimer’s disease. Biochem Biophys Res Commun 265: 335–338Google Scholar
  6. Emahazion T, Jobs M, Howell WM, Siegfried M, Wyoni PI, Prince JA, Brookes AJ (1999) Identification of 167 polymorphisms in 88 genes from candidate neuro-degeneration pathways. Gene 238: 315–324PubMedCrossRefGoogle Scholar
  7. Hawkins JW, Artinger M, Quigley ME (2001) Genomics and drug development: impacts and strategic implications. Decision Resources, Waltham, Mass, USA, pp 39–42Google Scholar
  8. Helbecque N, Berr C, Cottel D, Fromentin-David I, Sazdovitch V, Ricolfl F, Ducimetiere P, Di Menza C, Amouyel P (2001) VLDL receptor polymorphism, cognitive impairment, and dementia. Neurology 56: 1183–1188PubMedCrossRefGoogle Scholar
  9. Ji Y, Urakami K, Wada-Isoe K, Adachi Y, Nakashima K (2000) Estrogen receptor gene polymorphisms in patients with Alzheimer’s disease, vascular dementia and alcohol-associated dementia. Dement Geriatr Cogn Disord 11: 119–122PubMedCrossRefGoogle Scholar
  10. Kalaria RN (2001) Advances in molecular genetics and pathology of cerebrovascular disorders. Trends Neurosci 24: 392–400PubMedCrossRefGoogle Scholar
  11. Ki CS, Na DL, Kim DK, Kim HJ, Kim JW (2001) Lack of association of the interleukin-1 alpha gene polymorphism with Alzheimer’s disease in a Korean population. Ann Neurol 49: 817–818PubMedCrossRefGoogle Scholar
  12. Kolsch H, Ptok U, Bagli M, Papassotiropoulos A, Schmitz S, Barkow K, Kockler M, Rao ML, Maier W, Heun R (2001) Gene polymorphisms of interleukin-1 alpha influence the course of Alzheimer’s disease. Ann Neurol 49: 818–819PubMedCrossRefGoogle Scholar
  13. Kovacs DM (2000) alpha2-macroglobulin in late-onset Alzheimer’s disease. Exp Gerontol 35: 473–479Google Scholar
  14. Kunugi H, Ueki A, Otsuka M, Isse K, Hirasawa H, Kato N, Nabika T, Kobayashi S, Nanko S (2001) A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer’s disease. Mol Psychiatry 6: 83–86PubMedCrossRefGoogle Scholar
  15. Lambert JC, Chartier-Harlin MC, Cottel D, Richard F, Neuman E, Guez D, Legrain S, Berr C, Amouyel P, Helbecque N (1999) Is the LDL receptor-related protein involved in Alzheimer’s disease? Neurogenetics 2: 109–113PubMedCrossRefGoogle Scholar
  16. McCusker SM, Curran MD, Dynan KB, McCullagh CD, Urquhart DD, Middleton D, Patterson CC, Mcllroy SP, Passmore AP (2001) Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer’s disease and vascular dementia: a case-control study. Lancet 357: 436–439PubMedCrossRefGoogle Scholar
  17. Meng G, Yuan J, An L, Gong J, Zhu H, Cui S, Yu Z, Hu G (2000) An association study of polymorphisms in the alpha-antichymotrypsin gene for Alzheimer disease in Han-Chinese. Hum Mutat 16: 275–276PubMedCrossRefGoogle Scholar
  18. Pasinetti GM (2001) Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer’s disease dementia. J Neurosci Res 65: 471–476PubMedCrossRefGoogle Scholar
  19. Pericak-Vance MA, Bass MP, Yamaoka LH, Askell PC, Ott WK, Rwedow HA, Nold MM, Conneally PM, Small GW, Vance JM, Saunders AM, Roses AD, Haines JL (1997) Complete genomic screen in late-onset familial Alzheimer disease. J Am Med Assoc 278: 1237–1241CrossRefGoogle Scholar
  20. Perry RT, Collins JS, Harrell LE, Acton RT, Go RC (2001) Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to age-matched controls. Am J Med Genet 105: 332–342PubMedCrossRefGoogle Scholar
  21. Singleton AB, Gibson AM, McKeith IG, Ballard CG, Edwardson JA, Morris CM (2001) Nitric oxide synthase gene polymorphisms in Alzheimer’s disease and dementia with Lewy bodies. Neurosci Lett 303: 33–36PubMedCrossRefGoogle Scholar
  22. Song YQ, Rogaeva E, Premkumar S, Brindle N, Kawarai T, Orlacchio A, Yu G, Levesque G, Nishimura M, Ikeda M, Pei Y, O’Toole C, Duara R, Barker W, Sorbi S, Freedman M, Farrer L, St. George-Hyslop P (1998) Absence of association betweenAlzheimer disease and the -491 regulatory region polymorphism of APOE. Neurosci Lett 250: 189–192CrossRefGoogle Scholar
  23. Yoo JH, Choi GD, Kang SS (2000) Pathogenicity of thermolabile methylene-tetrahydrofolate reductase for vascular dementia. Arterioscler Thromb Vase Biol 20: 1921–1925CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2002

Authors and Affiliations

  • H. A. M. Mucke
    • 1
  1. 1.H. M. Pharma ConsultancyWienAustria

Personalised recommendations